Entering text into the input field will update the search result below

Fate lands new U.S. patent covering gene therapy

Aug. 16, 2017 10:47 AM ETFate Therapeutics, Inc. (FATE) StockBy: Douglas W. House, SA News Editor
  • The USPTO issues U.S. Patent No. 9,675,641 to Fate Therapeutics (NASDAQ:FATE -1.3%) covering the use of prostaglandins as viral transduction enhancers for the genetic modification of CD34+ hematopoietic cells. The patent, effective until 2029, is owned by the Indiana University Research and Technology Corporation and is licensed exclusively to Fate in all fields.

Recommended For You

More Trending News

About FATE Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
FATE--
Fate Therapeutics, Inc.